首页> 美国卫生研究院文献>Molecular Metabolism >Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression
【2h】

Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression

机译:肝脏脱碘酶1型早期诱导抑制NAFLD进展期间的肝胃蛋白酶

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nonalcoholic fatty liver disease (NAFLD) comprises a spectrum ranging from hepatosteatosis to progressive nonalcoholic steatohepatitis that can lead to cirrhosis. Humans with low levels of prohormone thyroxine (T4) have a higher incidence of NAFLD, and thyroid hormone treatment is very promising in all patients with NAFLD. Deiodinase type 1 (Dio1) is a hepatic enzyme that converts T4 to the bioactive T3 and therefore regulates thyroid hormone availability within hepatocytes. We investigated the role of this intrahepatic regulation during the progression of NAFLD.
机译:非酒精性脂肪肝疾病(NAFLD)包括一种从肝胃溶液中的谱到逐渐导致肝硬化的渐进性的非酒精性脂肪肝炎。具有低水平甲状腺素(T4)的人具有较高的NAFLD发病率,并且甲状腺激素治疗在所有NAFLD患者中非常有前景。脱碘酶型1(DIO1)是将T4转化为生物活性T3的肝酶,因此调节肝细胞内的甲状腺激素可用性。我们调查了在NAFLD进展过程中这种肝内调节的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号